TENX
Tenax Therapeutics·NASDAQ
--
--(--)
--
--(--)
0.97 / 10
Underperform
Fundamental analysis is concerning: the Net profit / Total profit (%) factor scores zero, and key margins are suboptimal, indicating poor profitability. Although current and fixed asset turnover ratios are high, they are insufficient to offset weak earnings quality, leading to an overall fundamental rating of Underperform.
Analysis Checks(3/5)
Inventory turnover ratio
Value29.85
Score2/3
Weight191.46%
1M Return-2.63%
Value29.85
Score2/3
Weight191.46%
1M Return-2.63%
Current assets turnover ratio
Value1.72
Score2/3
Weight-88.34%
1M Return1.15%
Value1.72
Score2/3
Weight-88.34%
1M Return1.15%
Net profit / Total profit (%)
Value100.00
Score0/3
Weight22.32%
1M Return-0.30%
Value100.00
Score0/3
Weight22.32%
1M Return-0.30%
Gross profit margin (%)
Value36.42
Score1/3
Weight38.92%
1M Return-0.54%
Value36.42
Score1/3
Weight38.92%
1M Return-0.54%
Fixed assets turnover ratio
Value831.40
Score3/3
Weight-64.36%
1M Return0.86%
Value831.40
Score3/3
Weight-64.36%
1M Return0.86%
Inventory turnover ratio
Value29.85
Score2/3
Weight191.46%
1M Return-2.63%
Value29.85
Score2/3
Weight191.46%
1M Return-2.63%
Gross profit margin (%)
Value36.42
Score1/3
Weight38.92%
1M Return-0.54%
Value36.42
Score1/3
Weight38.92%
1M Return-0.54%
Current assets turnover ratio
Value1.72
Score2/3
Weight-88.34%
1M Return1.15%
Value1.72
Score2/3
Weight-88.34%
1M Return1.15%
Fixed assets turnover ratio
Value831.40
Score3/3
Weight-64.36%
1M Return0.86%
Value831.40
Score3/3
Weight-64.36%
1M Return0.86%
Net profit / Total profit (%)
Value100.00
Score0/3
Weight22.32%
1M Return-0.30%
Value100.00
Score0/3
Weight22.32%
1M Return-0.30%
Is TENX fundamentally strong?
- TENX scores 0.97/10 on fundamentals and holds a Premium valuation at present. Backed by its -39.38% ROE, 0.00% net margin, -1.83 P/E ratio, 0.83 P/B ratio, and 94.33% earnings growth, these metrics solidify its Underperform investment rating.
